Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Orlistat vs Pramlintide: they're closely matched on evidence (6 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Orlistat and Pramlintide are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Orlistat and Pramlintide have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
With meals
Xenical 120 mg capsule (prescription formulation).
Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.
With meals
Subcutaneous pre-meal injection (Symlin / SymlinPen)
and 2 more not shown
and 1 more not shown
4–12 weeks to onset; maximal by 6–12 months
Year 2 of continuous use
Years
3–12 months
Weeks to 6-12 months
Per meal / weeks
Months
The label describes severe hypoglycaemia, when it occurs, within three hours after a Symlin injection; this is not a guarantee of no risk at other times.
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Diabetes Care (2004) · RCT · n=3305
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Lancet (1998) · RCT · n=688
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
JAMA (1999) · RCT · n=892
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Diabet Med (2004) · RCT · n=651
Double-blind, placebo-controlled, parallel-group multicentre trial in 651 patients with type 1 diabetes, mealtime pramlintide at varying doses or placebo added to insulin for 52 weeks.
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care (2002) · RCT · n=480
52-week double-blind, placebo-controlled trial in 480 patients with type 1 diabetes, pramlintide 30 µg four times daily or placebo added to insulin. At week 20, pramlintide patients whose HbA1c had fallen less than 1% by week 13 were re-randomised to 30 or 60 µg.
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care (2003) · RCT · n=656
52-week double-blind, placebo-controlled, parallel-group multicentre trial in 656 insulin-treated patients with type 2 diabetes, randomised to placebo or pramlintide 60 µg three times daily, 90 µg twice daily or 120 µg twice daily.
Both Orlistat and Pramlintide are closely matched — the best choice depends on your specific health goals.
For manage weight, Orlistat has a higher relevance score (72 vs 48).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.